Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

University Cancer & Blood Center launches Comprehensive Breast Health Program


University Cancer & Blood Center

“My dream for 30 years has been to take care of my patients with a truly comprehensive approach to breast cancer care.” – Dr. Cody Gunn

University Cancer & Blood Center (UCBC), a leading oncology and hematology practice for Northeast Georgia, is launching its Comprehensive Breast Health Program. It is a customized, personal approach to breast cancer treatment and prevention.

UCBC’s Comprehensive Breast Health Program features a complete staff of highly qualified and dedicated specialists providing state-of-the-art individualized care. This will be a complete and multidisciplinary approach, including surgical care, medical oncology, radiation oncology, and imaging with screening and diagnostic mammogram and ultrasound.

Services include a high-risk screening program that combines advanced technology with expert clinical assessment to determine a woman’s lifetime risk of breast cancer. Features include risk assessment using multiple computerized models to achieve the most accurate results. Women with an elevated lifetime risk of breast cancer may qualify for more intense screening with 3D mammogram and breast MRI as desired. Additional care includes physical examinations, genetic counseling and testing as indicated, and risk-reducing strategies.

“My dream for 30 years has been to take care of my patients with a truly comprehensive approach to breast cancer care,” says expert breast cancer surgeon, Dr. Cody Gunn. “To be able to work alongside UCBC’s medical and radiation oncologists as a part of one team is great for patient care. I believe our comprehensive, personalized care will have a significant positive impact on patient outcomes as well.“

The UCBC Comprehensive Breast Health Program is led by Dr. Gunn and Dr. Ashley Ray, the first fellowship-trained breast surgeon to practice in Athens. Their unique perspectives and backgrounds complement each other in their unified mission to help women prevent, treat, and return to full health after breast cancer treatment. Additionally, the staff specializes in the treatment of benign breast diseases.

The team includes Heather Wheatley, NP, who has long championed the High Risk Breast Clinic, and now Sarah Shanewise, PA, who assists in all facets of breast care. Casey Freeman is a certified nurse navigator who helps guide every woman through all aspects of her breast care.

While the doctors and their team will be seeing patients immediately at UCBC’s North Chase Street location, UCBC is in the process of building a standalone Comprehensive Cancer Center that is scheduled to open summer of 2023. This will be a destination site for all cancer care, including the Comprehensive Breast Health Program.

UCBC Comprehensive Breast Health Program appointments can be made by visiting UniversityCancer.com or by calling (762) 356-4780

Location: UCBC Comprehensive Breast Health Program, 658 N. Chase St., Suite 201, Athens.

Hours: Monday – Friday, 8:00 am to 5:00 pm

About UCBC

University Cancer & Blood Center has been Northeast Georgia’s leading cancer and hematology treatment center for over 40 years. Our highly skilled medical professionals, whose backgrounds include working at the nation’s leading cancer centers, provide every patient with the most advanced cancer care available in an atmosphere of care and compassion. For more information, visit universitycancer.com or call (706) 353-2990.

Share article on social media or email:

Next-Generation Sequencing Applications for Antiviral Drug Development & FDA Guidance for Data Submission, Upcoming Webinar Hosted by Xtalks


Gene variants can compromise virologic response and impact clinical outcomes.

Accurate detection and monitoring of minority variants that confer drug and antiviral resistance is critical to therapeutic and vaccine trials. Specifically, it aids in controlling the emergence of novel variants that can potentially lead to outbreaks of disease and breakthrough infections. Gene variants can compromise virologic response and impact clinical outcomes.

In this webinar the featured speaker explores the following case study:

Eurofins Viracor Biopharma has developed and validated a next-generation sequencing (NGS) assay to determine the genetic variability in the F gene of respiratory syncytial virus (RSV) isolated from human nasal swab (NS) specimens. The NGS method has several advantages over standard Sanger sequencing related to higher sensitivity, quantifiable, cost effective and automatable data analysis steps. The study utilized a deep sequencing approach to quantify minority variants. The patients in this study received a therapeutic targeting RSV. Defined proportions of artificial RNA and virus quasispecies were constructed and their relative proportions were measured using the NGS assay. The assay was validated for the performance characteristics such as analytical sensitivity, precision and accuracy.

To learn more about the applications of this NGS assay and get FDA guidance on data submission, register for this webinar on antiviral drug development.

Join Kirthi Kutumbaka, PhD, Senior Research Scientist, Eurofins Viracor Biopharma, for the live webinar on Friday, November 11, 2022, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Next-Generation Sequencing Applications for Antiviral Drug Development & FDA Guidance for Data Submission.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Kyowa Hakko Announces Glaxon’s Limited-Time Offer Becomes A Permanent Feature


Glaxon permanently adds IMMUSE™ to SuperGreens

Glaxon™, producer of sports nutrition dietary supplements, launched this summer a SuperGreens Enhanced Immune Edition that, in addition to the power of Glaxon™’s trademarked Supershrooms® Organic Mushroom Blend, included IMMUSE™, a postbiotic that provides immune support at a cellular level – both of which support the immune systems of its customers.

“The inclusion of IMMUSE™ was so successful that we decided to soft launch the SuperGreens Enhanced Immune Edition formula in all flavors: Lemon Iced Tea, Orchard Iced Tea, BurstBerry Iced Tea, Dragon Fruit, and the original, limited-time edition offering, Blueberry Açaí,” said Joey Savage, the visionary and formulator of SuperGreens Enhanced Immune Edition.

With a consumer base increasingly interested in immune health, the addition of IMMUSE™ was a logical next step for Glaxon™. Produced by Kyowa Hakko, an international health ingredient and pharmaceutical manufacturer, IMMUSE™ is a thoroughly researched immune activator, with 29 published studies and over ten years of research supporting its mode of action. Specifically, IMMUSE™ is a branded form of the LC-Plasma strain of lactic acid bacteria. These bacteria can activate plasmacytoid dendritic cells (pDCs), which, once triggered, circulate throughout the body mobilizing NK Cells, killer T cells, helper T cells, and B Cells for more comprehensive immune support.

SuperGreens Enhanced Immune Edition is loaded with antioxidants, superfoods, fiber, and enzymes to support the body further. For instance, the Supershrooms® Organic Mushroom Blend is designed to enhance mental focus, athletic support performance and provide beta-glucans to help with healthy white blood cells.*

Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc., commented, “Glaxon’s decision to include IMMUSE™ in all their SuperGreens formulations is indicative of their product innovation and the increasing consumer demand for effective, science-based immune ingredients.”

Through the addition of IMMUSE™ into the Glaxon™ SuperGreens formulations, Kyowa Hakko is joining a market that is expected to hit USD 11.5 billion by 2030. SuperGreens Immune formulas can be purchased via Glaxon™ or GNC. To learn more about IMMUSE™, go to https://immusehealth.com/.

*The Food and Drug Administration has not evaluated these statements. This product is not intended to diagnose, treat, cure or prevent any disease.

About IMMUSE:

IMMUSE™ is a postbiotic that delivers a new, breakthrough approach to broad range immune support*. As a clinically researched immune activator* supported by 29 published studies, including 14 human trials, IMMUSE™ proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, functions as a key leader of the immune system and has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. Its unique mechanism of action, discovered by Kyowa Hakko’s parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

About GLAXON™:

GLAXON™ is a brand of mold breaking dietary supplements with an emphasis on cross category lifestyle solutions beyond just the active nutrition space. GLAXON™ is one of the fastest growing brands in the space that has become an emerging leader in market innovation. Leveraging growth by disruptive thought-provoking branding, product education, and transparent supplements that provide lifestyle solutions. GLAXON™ is headquartered in a 100,000 sq ft facility of product incubation including: design, formulation, manufacturing, marketing, and sales. GLAXON™ headquarters is uniquely built to fast-track product concepts from R&D to fully finished products all under one roof remaining true to the company mantra, “Made with Real Science”. GLAXON™ can be found at GNC, GLAXON.com, and select retailers globally. For more information visit GLAXON.com or find us on Instagram and TikTok.

Share article on social media or email:

CareAparent Wins Gold Best In-Home Care and Bronze Best Physical Therapy Star Tribune Readers’ Choice Minnesota Best Awards for 2022


“…As a home health provider our core values are excellence, trust, compassion, collaboration, and safety. Receiving this honor affirms that we are living out those values and improving the lives of the clients we serve every day.” – Dominic Todora, President, CareAparent.

CareAparent, a premier provider of Home Health and Personal Cares in Minnesota for seniors living independently at home, is pleased to announce receiving the gold medal for Best In-Home Care and the bronze medal for Best In-Home Physical Therapy in Star Tribune Readers’ Choice Minnesota Best Awards for 2022.

“CareAparent is honored to be recognized by our clients and the public for the services and in-home care we provide. As a home health provider our core values are excellence, trust, compassion, collaboration, and safety. Receiving this honor affirms that we are living out those values and improving the lives of the clients we serve every day.” – Dominic Todora, President, CareAparent.

“Being recognized by Minnesota’s Best echoes the dedication our teams have for our clients. We are committed to providing quality care and our focus is, and will continue to be, excellence.” – Jose Colon, CareAparent Therapy Manager.

CareAparent is a trusted provider of home health and personal care services, including skilled nursing care, occupational therapy, physical therapy, personal care and hospice support. Accredited by the Joint Commission and certified under Medicare and Medicaid, CareAparent offers essential in-home care services throughout the Twin Cities, including veterans, whenever it’s needed, allowing our clients to continue enjoying life in a familiar, and comfortable environment. Passionate and experienced teams are available 24-hours a day and every day of the week, including weekends and holidays.

To learn more about CareAparent or schedule a complimentary consultation, please visit CareAparent.com.

Share article on social media or email:

Dr. Sergio Yero & Dr. Wilbert D. Yeung of Advanced Psychiatric Associates Named NJ Top Docs


News Image

NJ Top Docs has reviewed and approved Sergio Yero, MD, FAPA and Wilbert D. Yeung, MD of Advanced Psychiatric Associates as top doctors in the field of Psychiatry for 2022. Advanced Psychiatric Associates is a behavioral health group practice dedicated to providing the best possible care in a relaxed, comfortable private office setting.

They currently have three convenient locations in Hackensack, Glen Rock, and Florham Park.

Drs. Yero and Yeung treat children, adolescents, adults, and families with a variety of conditions including anxiety, depression, OCD, addiction, mood disorders, ADHD, and behavioral issues.

They provide a full range of therapies including Cognitive Behavioral Therapy, Couples and Family Therapy, FBT for Eating Disorders, Parent Guidance and Consultation, Psychodynamic Psychotherapy, Psychopharmacology, Suboxone Induction and Maintenance, and Supportive Psychotherapy.

Dr. Sergio Yero is Board Certified in both General Psychiatry and Addiction Psychiatry. His areas of expertise are psychopharmacology, addiction psychiatry, refractory psychiatric illnesses, personality and mood disorders.

To learn more about Dr. Yero, please visit: https://njtopdocs.com/nj-doctors/dr-sergio-yero/

Dr. Wilbert Yeung is Board Certified in General Psychiatry and Child & Adolescent Psychiatry. He is experienced in treating a wide range of conditions including mood disorders, depression, anxiety, OCD, ADHD, behavioral issues, and eating disorders. He completed a Triple Board Residency in Pediatrics, Psychiatry, Child and Adolescent Psychiatry at Brown University, where he was an Assistant Instructor and Chief Resident.

To learn more about Dr. Yeung, please visit: https://njtopdocs.com/nj-doctors/wilbertyeungmd/

—

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy-to-use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



SIUE School of Nursing Gains $4M HRSA Grant to Launch Mobile Health Unit and Training Enhancement Program


(L-R) Jerrica Ampadu, PhD, RN, CCP, associate professor, Amelia Perez, PhD, RN, associate professor, Rebecca Luebbert, PhD, PMHCNS-BC, professor, and Melissa Bogle, DNP, APRN, MPH, assistant professor

We are focused on promoting health equity by increasing access to care, growing the number of students who are prepared to address the social determinants of health within the community setting and training more underrepresented students in community health.

Southern Illinois University Edwardsville’s School of Nursing (SON) has received its largest grant in history— $4 million from the Health Resources and Services Administration (HRSA) — to develop a mobile health unit that will provide community-based services in East St. Louis, Fairmont City, and surrounding communities.

“We are focused on promoting health equity by increasing access to care, growing the number of students who are prepared to address the social determinants of health within the community setting and training more underrepresented students in community health,” said Principal Investigator (PI) Jerrica Ampadu, PhD, RN, CCP, associate professor, and director of the SIUE SON’s WE CARE Clinic in East St. Louis.

The four-year project is entitled, “Nurse education, practice, quality, and retention-mobile health training program – WE CARE REACH: Responding, educating, and advocating for community health.”

The mobile health unit, WE CARE REACH, will offer primary care and chronic care management services. It will be staffed by an interprofessional team of healthcare providers, including nurse practitioners, undergraduate and graduate nursing students, a social worker, a nutritionist and a pharmacist.

Co-PIs include the SON’s Amelia Perez, PhD, RN, associate professor, Rebecca Luebbert, PhD, PMHCNS-BC, professor, and Melissa Bogle, DNP, APRN, MPH, assistant professor. The team will design curriculum to enhance SIUE’s student training in underserved population groups during the creation of the new mobile health clinic. The project team will also engage in community outreach and education about the profession of nursing and recruit K-12 students into nursing.

“To educate nursing students on the social determinants of health, which include how racism impacts nursing and the deliverer of healthcare, students will participate in a Community Nurse Fellowship,” shared Ampadu. “Students will be immersed in community health for over 100 clinical hours learning with the interprofessional team and addressing health disparities.”

In addition to funding the mobile health unit, the HRSA grant provides undergraduate nursing students with $1,000 stipends to help increase their interest and ability to join the nursing workforce within underserved primary care settings.

The SON hopes the mobile unit will begin services in summer of 2023.

The School of Nursing’s programs are committed to creating excellence in nursing leadership through innovative teaching, evidence-based practice, quality research, patient advocacy and community service. Enrolling more than 1,700 students in its baccalaureate, master’s and doctoral programs, the School develops leaders in pursuit of shaping the nursing profession and impacting the health care environment. SIUE’s undergraduate nursing programs on the Edwardsville campus help to solve the region’s shortage of baccalaureate-prepared nurses and enhance the quality of nursing practice within all patient service venues. The School’s graduate programs prepare nurses for advanced roles in clinical practice, administration and education.

Share article on social media or email:

WCG FDAnews Announces the Clinical Trials Track at the 17th Annual FDA Inspections Summit, Nov. 16-18, 2022, Washington, DC


17th Annual FDA Inspections Summit

**Presented by WCG FDAnews**

Nov. 16-18, 2022 • Washington, DC

Inspections Summit (11/16-18) Clinical Trials Track

https://wcg.swoogo.com/fda-inspections-summit-2022

The Clinical Trials track at the 17th Annual FDA Inspections Summit has been carefully crafted to provide everything clinical trials professionals need to ensure inspection success.

FDA and clinical trial industry VIPs will lead every session and workshop will help attendees pass future inspections, no matter their current challenges.

The event begins with Elizabeth Miller, Pharm.D., assistant commissioner for medical products and tobacco operations in the Office of Regulatory Affairs at the FDA. She’ll discuss the latest plans and initiatives coming out of the agency so attendees can prepare for what’s to come in FDA inspections, whether on-site or virtual.

Members of the WCG Avoca Quality Consortium (AQC) will be a constant presence in the Clinical Trials track, guiding the sessions to help participants understand:


  • Purpose-Driven Inspection Preparedness: People, Process and Technology — Critical Components to Success


This panel will connect, collaborate, and explore how building quality relationships, planning processes proactively, and using current technology solutions brings inspection success in an environment where clinical trial professionals are often doing more with less. Panelists include Téa Romero, client success manager at Clario; Neala Lane, associate director, Quality Improvement Office at Indiana University; Trevor Cole, senior manager at WCG; and Gary Shorter, senior director of emerging technology and AI at IQVIA Tech.

  • The Potential — and Limitations — of Technology-Driven TMF Compliance


TMF-readiness is and will remain a key focus for inspections and a key pain point for sponsors and CROs. Can artificial intelligence and machine learning (AI/ML) or other automation fill this gap? This discussion addresses the promise and challenges associated with applying these approaches in a validated environment. Presented by Ted Finlan, senior vice president for project planning and administration at Worldwide Clinical Trials.

  • BIMO in Action: WCG AQC Members Share Insights from Their Recent Inspection Experiences    


This session will review significant updates to the Bioresearch Monitoring Program (BIMO) / Sponsors and Contract Research Organizations Program released in September 2021 and share feedback from members’ inspection experiences. Presented by Karen Harvey, senior director of the WCG Avoca Quality Consortium.

  • And hear directly from the FDA!


Engage in a session on validating systems and equipment for compliance with the FDA’s Francisco Vicenty, program manager, Case for Quality, and Daniel Walter, policy analyst. Attendees will have the opportunity to participate in a mock inspection with Simone Pitts (invited), FDA national expert, pharmaceutical.

This level of FDA and industry expertise with this combination of must-know topics can only be found at the 17th Annual FDA Inspections Summit’s Clinical Trials track.

Conference Details

17th Annual FDA Inspections Summit

**Presented by WCG FDAnews**

Nov. 16-18, 2022 • Washington, DC

https://wcg.swoogo.com/fda-inspections-summit-2022

Tuition:

Complete Summit $1,997

Additional pricing and livestreaming options are available online.

Easy Ways to Register:

Online: https://wcg.swoogo.com/fda-inspections-summit-2022

By phone: 888-838-5578 or 703-538-7600

About WCG FDAnews:

WCG FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on WCG FDAnews’ newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations. Learn more at fdanews.com.

Share article on social media or email:

Driving Outcomes in Medical Affairs — Leveraging Technology to Identify Successful MSL-KOL Relationships, Upcoming Webinar Hosted by Xtalks


“Medical Affairs teams are critically seeking better ways to communicate their value,” says Tim Mikhelashvili, Chair, Mentorship Committee at Medical Affairs Professional Society (MAPS).

The right key opinion leader or KOL identification — with whom medical science liaisons (MSL) communicate and engage — can transform the effectiveness of the medical affairs and field medical teams. The MSL-KOL relationship can be crucial to successful patient outcomes.

“Medical Affairs teams are critically seeking better ways to communicate their value,” says Tim Mikhelashvili, Chair, Mentorship Committee at Medical Affairs Professional Society (MAPS).

“The focus of their value proposition is shifting towards patient outcomes and the patient journey through all of their activities,” Mikhelashvili explains. “As a result, the MSL (medical science liaison) value is now best expressed not only in the data they collect and communicate, but primarily in the context of the data they are able to capture and translate clinically.”

Knowing whom to approach and how to connect with them in this ever-changing landscape is central to ensuring that the team can elevate new treatments and improve patient outcomes in a real-world setting. Seeking quality engagements — those that transform the treatment paradigm — and not just quantity of engagements, will be the yardstick by which medical affairs teams are measured in the future.

Register now to learn about moving the MSL-KOL relationships from perfunctory to powerful. Join the featured speakers in reviewing the importance of KOL Identification and management and learn how to leverage the right technology and tools to create a quality engagement.

Join experts from Anju, Erick Borg, PharmD, Customer Success Manager, Medical Affairs; Steve Anzuini, Senior Solutions Engineer, Medical Affairs; and John Coritz, Senior Director, Customer Success, for the live webinar on Wednesday, November 9, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Driving Outcomes in Medical Affairs — Leveraging Technology to Identify Successful MSL-KOL Relationships.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food, and medical device community. Every year, thousands of industry practitioners (from life science, food, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Cartessa Makes Foray Into Minimally Invasive Aesthetics Market With LipoAI


New LipoAI

“LipoAI delivers the energy much faster and more efficiently than previous technologies, and patients are more comfortable post-operatively. I have seen no issues with post-op numbness or hypersensitivity in the areas treated like other energy-based skin tightening devices.” – Carey Nease MD

Cartessa Aesthetics has built a reputation for identifying and marketing state-of-the-art non-invasive aesthetic technology since inception. Working closely with the leading global manufacturers, Cartessa looks for devices that offer a true benefit to providers and patients in the most high-demand treatment categories. The latest addition to their portfolio, LipoAI, represents the company’s move into the minimally invasive space. Introduced to an exclusive audience of current customers at their user forum in Scottsdale, Arizona last week, LipoAI offers a new, technologically superior, safe and minimally invasive adjunct to traditional liposuction to meet their patients’ body contouring needs. Cartessa is working closely with DEKA, the Italian manufacturer who brought the first generation of laser-assisted lipolysis (LAL) to market, to bring the newest advanced LAL technology into the aesthetic field in the form of LipoAI.

Utilizing 1444nm wavelength, the gold standard for fat and water absorption, LipoAI offers a shorter pulse duration to reach higher peak power and a higher frequency than previous generations; these advancements make LipoAI a faster, more controlled and more energy efficient device. LipoAI also boasts an exclusive AI Mode, which uses predictive algorithms to facilitate bi-communication between the provider and the device, adjusting energy delivery in real time to improve accuracy, safety and efficiency of energy distribution.

For nearly a decade, DEKA conducted extensive research in collaboration with leading Italian universities to analyze thousands of data points balancing the multiple variables such as laser energy, dosimetry, absorption coefficients and real-time temperature behavior. The result is AI Mode, a sophisticated, predictive algorithm that allows LipoAI to adapt to the provider’s technique, adjusting energy delivery intelligently and automatically.

“LipoAI delivers the energy much faster and more efficiently than previous technologies, and patients are more comfortable post-operatively,” said cosmetic surgeon Carey Nease, MD. “I have seen no issues with post-op numbness or hypersensitivity in the areas treated like other energy-based skin tightening devices.”

Cartessa is known for bringing cutting-edge technology from around the globe in every aesthetic category to the best aesthetic providers in North America. With leading products in major categories including RF microneedling, CO2, and laser hair removal, Cartessa is excited to introduce innovation in a category that marks the company’s first foray into minimally invasive procedures. The Aesthetic Society 2021 Aesthetic Plastic Surgery National Databank cites liposuction as the #1 surgical procedure performed. As a hugely popular procedure, with several limitations such as little to no skin retraction, extensive downtime, trauma to the surgeon and patient, and blood loss, LipoAI improves upon the previous generations of laser-assisted lipolysis to address a clear need in the marketplace.

“Not only is LipoAI a more powerful and intelligent device,” shared Gabe Lubin, Founder and CEO of Cartessa, “but LipoAI also produces a better patient experience: less bruising, minimal pain and less recovery time compared to other methods of liposuction, making the device a welcomed advancement for providers and their patients alike.”

LipoAI is available for U.S. providers with liposuction experience and is exclusive to Cartessa Aesthetics.

About Cartessa:

Cartessa Aesthetics is a leading North American aesthetic company focused on cutting-edge technology and industry leading customer support. Thanks to an independent business model and established relationships with top global manufacturers, Cartessa’s product portfolio offers true competitive advantages for practices and patients across every aesthetics category. Customers benefit from expertly vetted devices and end-to-end support to maximize the clinical outcomes and returns of their investment.

About DEKA M.E.L.A.

DEKA M.E.L.A. is a controlled company of the large multinational Italian group EL. EN., listed on the Star Segment of the Milan Stock Exchange (ELN.MI). The company, which has more than three decades of laser experience, chose DEKA as its company name which means attainment of perfection and excellence and is also “10” in Greek, the perfect number according to Pythagoras. The Florentine company is rooted in a culture that has made excellence of thought its dominant feature. Due to its invaluable cultural heritage and unique historical background, DEKA encompasses into its vision a promise of universal value: to turn every scientific discovery into a concrete benefit for physicians and patients, and to translate every technological innovation into ongoing improvements for the range of products and services it offers.

Share article on social media or email:

FitOn Appoints Healthcare Executive Deborah Gage to Board Of Directors


“It’s an exciting time to be in healthcare and health tech,” Gage shared. “Especially with an innovative and mission driven company like FitOn that has incredible growth metrics, a beloved consumer facing brand, and was founded by proven technology visionaries.”

FitOn, the No. 1 health & wellness platform with over 13+ million members announced the addition of Deborah Gage to their board of directors. She joins FitOn to accelerate its goal of delivering premium health and wellness care throughout the healthcare ecosystem.

“From the beginning, our goal has been to democratize digital health & wellness with a truly innovative, engaging and motivating solution that removes any barriers to entry for customers,” said Lindsay Cook, Founder & CEO of FitOn. “To deliver on our vision, we are continually expanding our technology driven solution and investing in building the best team in the world, including our board of directors. Deborah brings a wealth of experience leading innovative healthcare companies ranging from startups to Fortune 100 companies. I could not be more excited to have her join us as we continue transforming the healthcare system to improve access, consumer experiences and health outcomes.”

Deborah Gage is joining FitOn’s Board of Directors, which also includes David Schaller from Delta-v Capital, Yash Patel from Telstra Ventures and FitOn’s executive team.

Deborah is active as a limited partner of several funds and as an advisor to PE and Venture firms. In her most recent CEO role, Deborah was President and Chief Executive of Medecision from 2011 to 2021, where she led the turn-around and profitable growth of the company to over $100M, establishing the Company’s mission and market leading position as a digital transformation partner in care management and consumer engagement.

Before joining Medecision, Deborah was an early team member at the health industry’s leading analytics firm Truven Healthcare (then NASDAQ: MDST). She then served as CEO of several private equity and venture-backed Saas focused Healthcare firms which included SolutionPoint®, Inc., GTESS Corporation, and RosettaMed (acquired by Kryptiq).

“As an active entrepreneur and operator focused on improving healthcare access, I’ve seen just how much opportunity exists to improve the user experience and to impact health outcomes,” Gage said. “I have a passion for working with companies that are transforming their industries. With millions of active members on their platform, what FitOn has already accomplished is impressive and I believe it represents a model to deliver accessible and enjoyable healthcare solutions at a scale few other companies have achieved.”

“It’s an exciting time to be in healthcare and health tech,” Gage shared. “Especially with an innovative and mission driven company like FitOn that has incredible growth metrics, a beloved consumer facing brand, and was founded by proven technology visionaries.”

ABOUT FITON:

FitOn is the largest health & wellness platform providing instant access to the widest variety of premium workouts and health experiences, all from world class trainers, experts and celebrities. It works with top health plans and enterprise customers to drive best-in-class engagement through its digital platform, expansive network of fitness studios and gyms, and condition management courses. The FitOn Health platform provides the only truly integrated hybrid preventative care solution for employers and health plans to supercharge their benefits and help their members be more active, connect with coworkers, friends and family, and make leading a healthy lifestyle fun and motivating. FitOn members have shown their passion for the product by completing more than 1 billion workout minutes and leaving 400,000+ 5-Star reviews. Learn more at: https://health.fitonapp.com

For more information, please contact: press@fitonapp.com

Share article on social media or email: